⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of FELIQS Corporation and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
FELIQS Corporation
↗Fukuoka, Japan
FELIQS is a clinical-stage biotechnology company focused on ophthalmology, specifically targeting neonatal and aging-related eye diseases. The company leverages a proprietary drug discovery platform that identifies therapeutics modulating ferroptosis and oxidized-lipid pathways to address significant unmet medical needs.
Headquartered in Japan with a U.S. presence (FELIQS Inc.) in Bellevue, Washington, and previously associated with JLABS@NYC, the company is advancing a pipeline of small-molecule candidates. Their lead asset, FLQ-101, is being developed for the prevention of retinopathy of prematurity (ROP) and has received orphan drug and fast-track designations from the FDA.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2019
Ownership:private
Status:operating
FUNDING
Stage:Series A
Total Raised:$21.5M
Investors:Beyond Next Ventures, Keio Innovation Initiative (KII), Mitsubishi UFJ Capital, FFG Venture Business Partners, Japan Science and Technology Agency
PIPELINE
Stage:Phase 1
Lead Drug Stage:Phase 1b/2
Modalities:Small molecule
Active Trials:1
Trial Phases:Phase 1: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:FELIQS Inc. (U.S.)
Key Partnerships:Kyushu University (Academic origin/collaboration)
COMPETITION
Position:Emerging
Competitors:AcureX Biosciences, EyeCool Therapeutics
LEADERSHIP
Key Executives:
Ken-ichiro (Nobu) Kuninobu - Co-founder & CEO
Matt Fowler - CFO
Board Members:Gregory Kunst, Joe Zenkus
LINKS
Website:feliqs.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with FELIQS Corporation. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.